Navigation Links
Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer
Date:8/6/2009

Bellicum Founder, President and Chief Medical Officer, Kevin M. Slawin, M.D., stated, "This first clinical trial of BP-GMAX-CD1 is designed to establish proof of principle for our core iCD40 technology, which has been engineered to overcome the critical potency limitations of previous cancer vaccine strategies. Dosing the first patient is an exciting and significant milestone in our quest to deliver safer and more effective therapies to patients with advanced cancer."

The small-molecule dimerizer, AP1903, and the ARGENT(TM) cell-signaling regulation technology underlying BP-GMAX-CD1 were licensed from ARIAD Pharmaceuticals, Inc. AP1903 is designed to bring together two proteins and activate them. In the case of BP-GMAX-CD1, administration of AP1903 to patients leads to controlled activation of the ARGENT-regulated protein iCD40. AP1903 was previously shown by ARIAD to be well-tolerated with defined pharmacokinetics in a Phase 1 clinical trial.

"This is an exciting application of ARIAD's dimerizer technology, with the potential for therapeutic benefit linked to precise control of signaling events inside cells," stated Timothy P. Clackson, Ph.D., Senior Vice President and Chief Scientific Officer of ARIAD. "We congratulate Bellicum on this first application of the dimerizer technology in cancer patients."

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response. The company's lead product, BP-GMAX-CD1, a genetically modified, pharmacologically regulated autologous vaccine, is in clinical development for patients with advanced,
'/>"/>

SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bellicum Pharmaceuticals Announces $3.75 Million in Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health Limited ... brand Nature’s Way, Marc St-Onge has affirmed his commitment ... is an integral part of the agreement with Nature’s ... further develop Ascenta Skin into a leading player in ... breakthrough, anti-aging skincare supplement featuring 6 active ingredients including ...
(Date:5/22/2015)... May 22, 2015 “It’s like ... SLP, RAC-CT, CHHRP-QT, Vice President of Clinical Operations/Education ... important ‘language’ that impacts how care is coded ... in long term care reimbursement, operations and compliance ... and talent management, launches a new series of ...
(Date:5/22/2015)... Memorial Day weekend is typically considered the beginning of ... tips to help promote safe travel. , According to estimates ... fatalities this Memorial Day weekend. Amica is sharing the following ... , , Always wear a seatbelt: ... whether they’re driving or riding along as a passenger. Seatbelts ...
(Date:5/22/2015)... Virginia (PRWEB) May 22, 2015 ... of Health IT solutions, announced today that Bill ... Healthcare is the developer of BlueEHS,a first of ... BlueEHS offers a customizable Electronic Health Records (EHR) ... lab interfaces, a telemedicine-enabled comprehensive patient portal, and ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2
... ... Headache Society® and the Migraine Research Foundation are pleased to announce that Anna ... for her proposal, “Corticothalamic feedback and trigeminothalamic sensory processing during cortical spreading depression-relevance ... ...
... ... Recent Documentary, Comes To Race—and To Educate Others,About the Link Between Oral Health and Heart ... Vista, CA (PRWEB) ... will stand out more than most—but she’ll do it seated in her wheelchair. That person ...
... ... a group of individuals who started a company that specialize in the R&D and ... have decided to kickstart the commercial launch of its High Definition reading glasses named ... (PRWEB) ...
... , In patients with leukemia, the formation of white ... leukemia patients particularly susceptible to infections, because properly functioning white ... bacteria. In the US alone, every year around 50.000 adults ... interplay of various factors , Leukemia occurs in various ...
... institutions housing innumerable units, sections and visitor destinations. ... within most locales, making it difficult to comply with ... addition, about half of all Americans approximately 90 ... hospital,s written signs. These challenges have led to ...
... 2010 Although caffeine is the most widely ... for maintenance of proper brain functioning has only ... from epidemiological studies and fundamental research in animal ... the cognitive decline seen in dementia and Alzheimer,s ...
Cached Medicine News:Health News:Thomas E. Heftler Migraine Research Award 2Health News:First Paraplegic Woman to Climb Mt. Kilimanjaro to Race at Vista's Strawberry Festival 2Health News:Introducing a New Generation of Reading and Computer Glasses 2Health News:Introducing a New Generation of Reading and Computer Glasses 3Health News:Gene loss causes leukemia 2Health News:UC design innovation: Healing for hospital signs that don't work 2Health News:UC design innovation: Healing for hospital signs that don't work 3Health News:UC design innovation: Healing for hospital signs that don't work 4Health News:New evidence caffeine may slow Alzheimer's disease and other dementias, restore cognitive function 2
(Date:5/21/2015)... , May 21, 2015  When ... along the side of his neck, he ... took a couple weeks off from weight ... go away.                               A ... 26, was referred to Michel Kliot, ...
(Date:5/21/2015)... , May 21, 2015 ... has announced the addition of the ... their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... and size the world market for Arthroscopy ... identifies trends impacting the market for these ...
(Date:5/21/2015)... , May 21, 2015  (MUSE Booth # ... Health Record (EHR) is invaluable in any hospital ... are now a requirement and mainstream in healthcare, ... into the EHR is gaining traction in MEDITECH ... Holmes, RN, Site Project Manager & Clinical Analyst ...
Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Hospital Streamlines ICU Efficiency with Timely Data Integration 2Hospital Streamlines ICU Efficiency with Timely Data Integration 3
... Trial Supported by the Foundation Fighting Blindness ... New England Journal of Medicine, OWINGS MILLS, Md., April ... to patients who were nearly blind from,a condition known as ... Initial results from the clinical trial, which was,funded in part ...
... April 26 Schering-Plough Corporation,(NYSE: SGP ) ... analysis of,an ongoing Phase II study of boceprevir, ... treatment-naive patients with chronic,hepatitis C virus (HCV) genotype ... the European Association for the Study of the ...
Cached Medicine Technology:Gene Therapy Provides Vision to People who Were Nearly Blind 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9
... developed a minimally invasive cryocatheter to ... delivers a very high level of ... site precision, minimal tissue disruption, and ... ,Freezor Xtra allows physicians to surgically ...
The Medtronic StableMapr catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing associated...
... The NAVI-STAR catheter is specifically designed for ... Our precision EP deflectable NAVI-STAR catheter houses ... tip to indicate, in real time, exact ... simultaneously collecting local electrogram information. The NAVI-STAR ...
... Biosense Webster offers a complete ... mapping in the atrium. The ISMUS ... for simple placement in the atrial ... on the catheter's distal tip permit ...
Medicine Products: